{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:00:52Z","timestamp":1795057252131,"version":"4.10.2"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2021.07538"],"award-info":[{"award-number":["2021.07538"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011749","name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","doi-asserted-by":"publisher","award":["2987602"],"award-info":[{"award-number":["2987602"]}],"id":[{"id":"10.13039\/100011749","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119750","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T10:17:57Z","timestamp":1785233877000},"page":"119750","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["High-throughput screening identification of USP7 inhibitors reveals YM155 as a biologically active scaffold with in vivo antitumor efficacy"],"prefix":"10.1016","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1511-4364","authenticated-orcid":false,"given":"Rita I.","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2467-9401","authenticated-orcid":false,"given":"Caio","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6470-969X","authenticated-orcid":false,"given":"Rahaf","family":"Habboub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1378-0029","authenticated-orcid":false,"given":"David","family":"Eisenbarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-2879","authenticated-orcid":false,"given":"Ana S.","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.R.","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119750_bib1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","article-title":"\"The ubiquitin code","volume":"81","author":"Komander","year":"2012","journal-title":"Annu. Rev. Biochem."},{"issue":"6","key":"10.1016\/j.biopha.2026.119750_bib2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.cbpa.2004.09.009","article-title":"\"Polyubiquitin chains: polymeric protein signals","volume":"8","author":"Pickart","year":"2004","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"\"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2026.119750_bib4","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202311171","article-title":"\"The emerging roles of non-canonical ubiquitination in proteostasis and beyond","volume":"223","author":"Akizuki","year":"2024","journal-title":"J. Cell. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119750_bib5","article-title":"\"The role of ubiquitination in health and disease","volume":"5","author":"Liao","year":"2024","journal-title":"MedComm (2020)"},{"issue":"5","key":"10.1016\/j.biopha.2026.119750_bib6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q","article-title":"\"Ubiquitin-mediated proteolysis: biological regulation via destruction,\"","volume":"22","author":"Ciechanover","year":"2000","journal-title":"Bioessays"},{"issue":"2","key":"10.1016\/j.biopha.2026.119750_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"\"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell."},{"issue":"4","key":"10.1016\/j.biopha.2026.119750_bib8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/cr.2016.39","article-title":"\"Ubiquitin modifications","volume":"26","author":"Swatek","year":"2016","journal-title":"Cell. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib9","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016808","article-title":"\"Ubiquitin-dependent sorting in endocytosis","volume":"6","author":"Piper","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119750_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/cr.2016.40","article-title":"\"Ubiquitin signaling in immune responses","volume":"26","author":"Hu","year":"2016","journal-title":"Cell. Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib11","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1038\/s41467-022-30376-7","article-title":"\"Deubiquitinating enzymes and the proteasome regulate preferential sets of ubiquitin substrates","volume":"13","author":"Trulsson","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119750_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.1005727","article-title":"\"Highlights in USP7 inhibitors for cancer treatment","volume":"10","author":"Oliveira","year":"2022","journal-title":"Front. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2026.119750_bib13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1080\/14728222.2023.2266571","article-title":"\"Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment","volume":"27","author":"Carreira","year":"2023","journal-title":"Expert. Opin. Ther. Targets"},{"key":"10.1016\/j.biopha.2026.119750_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116323","article-title":"\"Ubiquitin-specific proteases: From biological functions to potential therapeutic applications in gastric cancer","volume":"173","author":"Li","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.biopha.2026.119750_bib15","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1093\/emboj\/16.7.1519","article-title":"\"A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein","volume":"16","author":"Everett","year":"1997","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.biopha.2026.119750_bib16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S1097-2765(04)00157-1","article-title":"\"A dynamic role of HAUSP in the p53-Mdm2 pathway","volume":"13","author":"Li","year":"2004","journal-title":"Mol. Cell."},{"issue":"146","key":"10.1016\/j.biopha.2026.119750_bib17","doi-asserted-by":"crossref","first-page":"ra80","DOI":"10.1126\/scisignal.2001462","article-title":"DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination","volume":"3","author":"Du","year":"2010","journal-title":"Sci. Signal."},{"issue":"6","key":"10.1016\/j.biopha.2026.119750_bib18","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1172\/JCI85747","article-title":"\"Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis","volume":"126","author":"Wang","year":"2016","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2026.119750_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ebiom.2016.10.018","article-title":"\"Ubiquitin-specific protease-7 inhibition impairs Tip60-dependent Foxp3+ T-regulatory cell function and promotes antitumor immunity","volume":"13","author":"Wang","year":"2016","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.biopha.2026.119750_bib20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.immuni.2013.05.018","article-title":"\"Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity","volume":"39","author":"van Loosdregt","year":"2013","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.biopha.2026.119750_bib21","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/nm.4180","article-title":"\"HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma","volume":"22","author":"Tavana","year":"2016","journal-title":"Nat. Med."},{"issue":"7214","key":"10.1016\/j.biopha.2026.119750_bib22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nature07290","article-title":"\"The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network","volume":"455","author":"Song","year":"2008","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.biopha.2026.119750_bib23","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/15384101.2015.1007785","article-title":"\"USP7 deubiquitinase promotes ubiquitin-dependent DNA damage signaling by stabilizing RNF168","volume":"14","author":"Zhu","year":"2015","journal-title":"Cell. Cycle"},{"issue":"10","key":"10.1016\/j.biopha.2026.119750_bib24","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1172\/JCI120518","article-title":"\"Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis","volume":"128","author":"Su","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.biopha.2026.119750_bib25","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41418-023-01180-7","article-title":"\"Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1","volume":"30","author":"Yi","year":"2023","journal-title":"Cell. Death Differ."},{"issue":"47","key":"10.1016\/j.biopha.2026.119750_bib26","doi-asserted-by":"crossref","first-page":"77096","DOI":"10.18632\/oncotarget.12801","article-title":"\"CDDO-Me reveals USP7 as a novel target in ovarian cancer cells","volume":"7","author":"Qin","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.biopha.2026.119750_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114917","article-title":"\"USP7 deubiquitinates KRAS and promotes non-small cell lung cancer","volume":"43","author":"Huang","year":"2024","journal-title":"Cell. Rep."},{"key":"10.1016\/j.biopha.2026.119750_bib28","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.bcp.2017.02.011","article-title":"\"USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth","volume":"131","author":"An","year":"2017","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119750_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110675","article-title":"\"Ubiquitin-specific protease 7 promotes the growth and oncogenic potential of acute myeloid leukemia cells through the deubiquitination and upregulation of LRRK2","volume":"301","author":"Park","year":"2025","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2026.119750_bib30","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","article-title":"\"A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance","volume":"22","author":"Chauhan","year":"2012","journal-title":"Cancer Cell."},{"issue":"8","key":"10.1016\/j.biopha.2026.119750_bib31","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/1535-7163.MCT-09-0097","article-title":"\"Small-molecule inhibitor of USP7\/HAUSP ubiquitin protease stabilizes and activates p53 in cells","volume":"8","author":"Colland","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.biopha.2026.119750_bib32","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.chembiol.2012.02.007","article-title":"\"Discovery of specific inhibitors of human USP7\/HAUSP deubiquitinating enzyme","volume":"19","author":"Reverdy","year":"2012","journal-title":"Chem. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119750_bib33","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.bmcl.2017.01.018","article-title":"\"Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors","volume":"27","author":"Chen","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"7677","key":"10.1016\/j.biopha.2026.119750_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature24451","article-title":"\"Molecular basis of USP7 inhibition by selective small-molecule inhibitors","volume":"550","author":"Turnbull","year":"2017","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.biopha.2026.119750_bib35","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.chembiol.2017.09.003","article-title":"\"Structure-guided development of a potent and selective non-covalent active-site inhibitor of USP7","volume":"24","author":"Lamberto","year":"2017","journal-title":"Cell. Chem. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib36","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1038\/s41598-020-62076-x","article-title":"\"Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism","volume":"10","author":"Schauer","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119750_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112279","article-title":"\"N-benzylpiperidinol derivatives as novel USP7 inhibitors: Structure-activity relationships and X-ray crystallographic studies","volume":"199","author":"Li","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"24","key":"10.1016\/j.biopha.2026.119750_bib38","doi-asserted-by":"crossref","first-page":"10056","DOI":"10.1021\/acs.jmedchem.7b01293","article-title":"\"Discovery of small-molecule inhibitors of ubiquitin specific protease 7 (USP7) using integrated NMR and in silico techniques","volume":"60","author":"Di Lello","year":"2017","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2026.119750_bib39","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/1535-7163.MCT-20-0184","article-title":"\"Novel, selective inhibitors of USP7 uncover multiple mechanisms of antitumor activity in vitro and in vivo","volume":"19","author":"Ohol","year":"2020","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.biopha.2026.119750_bib40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1349-7006.2010.01834.x","article-title":"\"Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models","volume":"102","author":"Nakahara","year":"2011","journal-title":"Cancer Sci."},{"issue":"22","key":"10.1016\/j.biopha.2026.119750_bib41","first-page":"6376","article-title":"\"The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice","volume":"62","author":"Wu","year":"2002","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.biopha.2026.119750_bib42","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/1940-6207.CAPR-09-0085","article-title":"\"Triterpenoids CDDO-methyl ester or CDDO-ethyl amide and rexinoids LG100268 or NRX194204 for prevention and treatment of lung cancer in mice","volume":"2","author":"Liby","year":"2009","journal-title":"Cancer Prev. Res."},{"issue":"11","key":"10.1016\/j.biopha.2026.119750_bib43","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1940-6207.CAPR-10-0197","article-title":"\"Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer","volume":"3","author":"Liby","year":"2010","journal-title":"Cancer Prev. Res."},{"issue":"6","key":"10.1016\/j.biopha.2026.119750_bib44","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1021\/ci900056c","article-title":"\"Comparison of several molecular docking programs: pose prediction and virtual screening accuracy","volume":"49","author":"Cross","year":"2009","journal-title":"J. Chem. Inf. Model."},{"issue":"W1","key":"10.1016\/j.biopha.2026.119750_bib45","doi-asserted-by":"crossref","first-page":"W443","DOI":"10.1093\/nar\/gkv315","article-title":"\"PLIP: fully automated protein-ligand interaction profiler","volume":"43","author":"Salentin","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.biopha.2026.119750_bib46","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/CAD.0b013e328344ac68","article-title":"\"YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model","volume":"22","author":"Nakahara","year":"2011","journal-title":"Anticancer. Drugs"},{"issue":"22","key":"10.1016\/j.biopha.2026.119750_bib47","doi-asserted-by":"crossref","first-page":"10578","DOI":"10.1073\/pnas.89.22.10578","article-title":"\"Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease","volume":"89","author":"Guy","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.biopha.2026.119750_bib48","first-page":"954","article-title":"\"Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease","volume":"12","author":"Guy","year":"1992","journal-title":"Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119750_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.100896","article-title":"\"Identification of deubiquitinase inhibitors via high-throughput screening using a fluorogenic ubiquitin-rhodamine assay","volume":"2","author":"Varca","year":"2021","journal-title":"STAR Protoc."},{"issue":"3","key":"10.1016\/j.biopha.2026.119750_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1517\/17460441003605098","article-title":"\"Lipophilicity in drug discovery","volume":"5","author":"Waring","year":"2010","journal-title":"Expert. Opin. Drug. Discov."},{"issue":"1-3","key":"10.1016\/j.biopha.2026.119750_bib51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"\"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug. Deliv. Rev."},{"issue":"11","key":"10.1016\/j.biopha.2026.119750_bib52","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/nrd2445","article-title":"\"The influence of drug-like concepts on decision-making in medicinal chemistry","volume":"6","author":"Leeson","year":"2007","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"2","key":"10.1016\/j.biopha.2026.119750_bib53","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/108705719900400206","article-title":"\"A simple statistical parameter for use in evaluation and validation of high throughput screening assays","volume":"4","author":"Zhang","year":"1999","journal-title":"J. Biomol. Screen."},{"issue":"2","key":"10.1016\/j.biopha.2026.119750_bib54","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.biopha.2007.06.012","article-title":"\"A review of high throughput technology for the screening of natural products","volume":"62","author":"Mishra","year":"2008","journal-title":"Biomed. Pharmacother."},{"issue":"6","key":"10.1016\/j.biopha.2026.119750_bib55","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.chembiol.2010.05.013","article-title":"\"Probing the probes: fitness factors for small molecule tools","volume":"17","author":"Workman","year":"2010","journal-title":"Chem. Biol."},{"issue":"8","key":"10.1016\/j.biopha.2026.119750_bib56","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nchembio.1867","article-title":"\"The promise and peril of chemical probes","volume":"11","author":"Arrowsmith","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119750_bib57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nsmb1067","article-title":"\"Molecular recognition of p53 and MDM2 by USP7\/HAUSP","volume":"13","author":"Sheng","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119750_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109693","article-title":"\"Ubiquitin-specific protease 7 inhibitors reveal a differentiated mechanism of p53-driven anti-cancer activity","volume":"27","author":"Futran","year":"2024","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.biopha.2026.119750_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188903","article-title":"\"USP7 - a crucial regulator of cancer hallmarks","volume":"1878","author":"Saha","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119750_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12040762","article-title":"\"USP7 deregulation impairs S phase specific DNA repair after irradiation in breast cancer cells","volume":"12","author":"Vogt","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119750_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2025.101192","article-title":"\"The deubiquitinase USP7 stabilizes HER2 expression and promotes breast cancer progression","volume":"66","author":"He","year":"2025","journal-title":"Neoplasia"},{"key":"10.1016\/j.biopha.2026.119750_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12916-015-0416-2","article-title":"\"Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer","volume":"13","author":"Sonnenblick","year":"2015","journal-title":"BMC Med."},{"issue":"16","key":"10.1016\/j.biopha.2026.119750_bib63","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","article-title":"\"Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics","volume":"14","author":"Mita","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119750_bib64","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.canlet.2021.05.027","article-title":"\"Transgenic mouse models of breast cancer","volume":"516","author":"Regua","year":"2021","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib65","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0092-8674(88)90184-5","article-title":"\"Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene","volume":"54","author":"Muller","year":"1988","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2026.119750_bib66","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41388-020-01560-0","article-title":"\"Insights from transgenic mouse models of PyMT-induced breast cancer: recapitulating human breast cancer progression in vivo","volume":"40","author":"Attalla","year":"2021","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.biopha.2026.119750_bib67","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.3390\/cimb45060286","article-title":"\"Characterization of mammary tumors arising from MMTV-PyVT transgenic mice","volume":"45","author":"Liu","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"17","key":"10.1016\/j.biopha.2026.119750_bib68","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"\"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119750_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2026.111951","article-title":"\"Molecular actions of sepantronium bromide (YM155) on survivin-dependent cell death in cancer and beyond","volume":"427","author":"Marques","year":"2026","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.biopha.2026.119750_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106343","article-title":"\"YM155 inhibits neuroblastoma growth through degradation of MYCN: a new role as a USP7 inhibitor","volume":"181","author":"Li","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib71","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"\"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib72","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.molcel.2011.06.034","article-title":"\"Mechanism of USP7\/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase","volume":"44","author":"Faesen","year":"2011","journal-title":"Mol. Cell."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41467-018-08231-5","article-title":"\"Kinetic analysis of multistep USP7 mechanism shows critical role for target protein in activity","volume":"10","author":"Kim","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jsb.2016.05.005","article-title":"\"Structure of USP7 catalytic domain and three Ubl-domains reveals a connector alpha-helix with regulatory role","volume":"195","author":"Kim","year":"2016","journal-title":"J. Struct. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119750_bib75","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bph.12935","article-title":"\"YM155 down-regulates survivin and XIAP, modulates autophagy and induces autophagy-dependent DNA damage in breast cancer cells","volume":"172","author":"Cheng","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119750_bib76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-020-04112-1","article-title":"\"Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer","volume":"86","author":"Shimizu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119750_bib77","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1535-7163.MCT-21-0619","article-title":"\"YM155 induces DNA damage and cell death in anaplastic thyroid cancer cells by inhibiting DNA topoisomerase iialpha at the ATP-binding site","volume":"21","author":"Mackay","year":"2022","journal-title":"Mol. Cancer Ther."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:51:32Z","timestamp":1787179892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":77,"alternative-id":["S0753332226007869"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119750","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-throughput screening identification of USP7 inhibitors reveals YM155 as a biologically active scaffold with in vivo antitumor efficacy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119750","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119750"}}